- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01689389
Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study
Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
-
Argenteuil Cedex, Frankrijk
- Research Site
-
Belley, Frankrijk
- Research Site
-
Castelmaurou, Frankrijk
- Research Site
-
Cavaillon, Frankrijk
- Reserach Site
-
Les Mureaux, Frankrijk
- Research Site
-
Lille, Frankrijk
- Research Site
-
Marseille, Frankrijk
- Research Site
-
Montpellier, Frankrijk
- Research Site
-
Nimes Cedex, Frankrijk
- Research Site
-
Obernai, Frankrijk
- Research Site
-
Paris, Frankrijk
- Research Site
-
Rennes, Frankrijk
- Research Site
-
Saintes Cedex, Frankrijk
- Research Site
-
Sens, Frankrijk
- Research Site
-
St Dizier, Frankrijk
- Research Site
-
St Egreve Cedex, Frankrijk
- Research Site
-
Toulouse, Frankrijk
- Research Site
-
Tours, Frankrijk
- Research Site
-
Ussel Cedex, Frankrijk
- Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- New patients treated with Xeroquel XR
- Patients aged 18 years and over
- Diagnosis of bipolar disorder or schizophrenia according to DSM-IV criteria
Exclusion Criteria:
- Patient included in a therapeutic trial (Huriet-Serusclat Act)
- Patient refusing to participate in the study
- Pregnant women
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
---|
Main study population
All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age. Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months. |
Schizophrenia SoC sample
Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
|
Bipolar SoC sample
Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09].
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Descriptive analysis of variables related with how the drug is prescribed and used by the patient.
Tijdsspanne: At inclusion
|
Variables related with how the drug is prescribed and used by the patient [doses in mg/day, titration (yes/no), time of administration (morning/middle of the day/afternoon/evening), concomitant treatments] are going to be described.
|
At inclusion
|
Description of patient's socio-demographics profile.
Tijdsspanne: At inclusion
|
Age, gender, educational and professional status, co-habitation are going to be described.
|
At inclusion
|
Descriptive analysis of medical history.
Tijdsspanne: At inclusion
|
Diagnosis, family history of psychiatric disorders, number of suicidal attempts within the last 12 months, co-morbidities, treatments received during the last 12 months, laboratory and exam data will be included in the description.
|
At inclusion
|
Severity of the disease measured by Clinical Global Impressions Scale - Severity (CGI-S).
Tijdsspanne: At inclusion
|
The Clinical Global Impressions Scale - Severity (CGI-S) assesses the clinician's impression of the current state of the patient's illness. The following scores can be given: 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill patients. |
At inclusion
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change in Clinical Global Impressions Scale - Severity (CGI-S) during the treatment.
Tijdsspanne: From baseline to 12 months
|
The Clinical Global Impressions Scale - Severity (CGI-S) assesses the clinician's impression of the current state of the patient's illness. The following scores can be given: 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill patients. |
From baseline to 12 months
|
Quetiapine XR and concomitant treatment stop, stop date, reasons to stop, restart, restart date, reasons to restart.
Tijdsspanne: From baseline to 12 months
|
From baseline to 12 months
|
|
Descriptive analysis of the treatment changes: drug switches.
Tijdsspanne: From baseline to 12 months
|
From baseline to 12 months
|
|
Description of patterns of healthcare management resource use related with psychiatric disorders under investigation.
Tijdsspanne: From baseline to 12 months
|
From baseline to 12 months
|
|
Change in Body Mass Index (BMI).
Tijdsspanne: From baseline to 12 months
|
From baseline to 12 months
|
|
Laboratory tests- cholesterol.
Tijdsspanne: From baseline to 12 months
|
Blood test- cholesterol.
|
From baseline to 12 months
|
Descriptive analysis of all adverse events.
Tijdsspanne: From baseline to 12 months
|
From baseline to 12 months
|
|
Relapses (only for the schizophrenia subpopulation).
Tijdsspanne: From baseline to 12 months
|
New psychiatric hospitalisation, deterioration of the CGI-S (Clinical Global Impressions Scale - Severity) by at least 3 points for a baseline score of 1, at least 2 points for a baseline score of 2 or 3, at least 1 point for a baseline score of 4.
|
From baseline to 12 months
|
Laboratory tests- glycemia.
Tijdsspanne: From baseline to 12 months
|
Blood test- glycemia.
|
From baseline to 12 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Bruno FALISSARD, Pr, Paris
- Hoofdonderzoeker: Pierre-Michel LLORCA, Pr, Clermont-Ferrand
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NIS-NFR-SER-2012/1
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .